Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,678,896
  • Shares Outstanding, K 1,265,146
  • Annual Sales, $ 22,127 M
  • Annual Income, $ 5,455 M
  • 60-Month Beta 1.11
  • Price/Sales 3.61
  • Price/Cash Flow 8.63
  • Price/Book 3.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 1.57
  • Number of Estimates 8
  • High Estimate 1.64
  • Low Estimate 1.41
  • Prior Year 1.34
  • Growth Rate Est. (year over year) +17.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.57 +0.66%
on 01/17/20
67.40 -6.56%
on 12/23/19
-3.22 (-4.86%)
since 12/17/19
3-Month
62.38 +0.96%
on 11/14/19
68.16 -7.60%
on 12/12/19
-2.25 (-3.45%)
since 10/17/19
52-Week
60.89 +3.43%
on 10/03/19
70.50 -10.67%
on 02/01/19
-5.67 (-8.26%)
since 01/17/19

Most Recent Stories

More News
GILD or EXEL: Which Is the Better Value Stock Right Now?

GILD vs. EXEL: Which Stock Is the Better Value Option?

GILD : 62.98 (-0.35%)
EXEL : 19.82 (-3.03%)
Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction

Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.

PFE : 40.51 (-0.25%)
LLY : 139.58 (-1.31%)
NVO : 61.31 (unch)
GILD : 62.98 (-0.35%)
Nektar's Pain Drug Gets Adverse Advisory Committee Decision

Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.

LLY : 139.58 (-1.31%)
BMY : 66.72 (-0.09%)
GILD : 62.98 (-0.35%)
NKTR : 22.48 (-5.94%)
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $64.31, moving -1.11% from the previous trading session.

GILD : 62.98 (-0.35%)
The Zacks Analyst Blog Highlights: Chevron, Accenture, Adobe Systems, Gilead Sciences and Honda Motor

The Zacks Analyst Blog Highlights: Chevron, Accenture, Adobe Systems, Gilead Sciences and Honda Motor

HMC : 27.78 (+0.51%)
ADBE : 349.74 (+1.26%)
GILD : 62.98 (-0.35%)
CVX : 115.58 (-1.12%)
ACN : 209.20 (+0.11%)
Sarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of Directors

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that it has appointed John C. Martin, Ph.D., to its Board of Directors, effective today....

GILD : 62.98 (-0.35%)
SRPT : 127.90 (-1.84%)
Aptevo Therapeutics' Apvo436 Selected For Inclusion In The Leukemia & Lymphoma Society's Groundbreaking Beat Aml(R) Master Clinical Trial

APVO436 is the Latest Investigational AML Therapeutic to be Selected for Participation in the Study; Aptevo Joins Industry Leaders, Bristol-Myers Squib (formerly Celgene) Alexion Pharmaceuticals, Gilead...

AGIO : 52.86 (+2.54%)
ALXN : 113.27 (+0.68%)
ALPMF : 17.4200 (+0.87%)
CELGZ : 0.47 (+2.15%)
GILD : 62.98 (-0.35%)
APVO : 0.68 (-2.16%)
Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences

Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for serious autoimmune diseases, announced today that it has raised $25 million in a Series A investment from...

CELGZ : 0.47 (+2.15%)
GILD : 62.98 (-0.35%)
Stock Research Reports for Chevron, Accenture, Adobe & Others

Stock Research Reports for Chevron, Accenture, Adobe & Others

HMC : 27.78 (+0.51%)
GILD : 62.98 (-0.35%)
CVX : 115.58 (-1.12%)
CHTR : 502.73 (-1.19%)
ADBE : 349.74 (+1.26%)
ACN : 209.20 (+0.11%)
Technological Advancements Expand Biopharmaceuticals' Production Capabilities

The biopharmaceutical industry is driven by multiple factors, all while rapidly evolving in the digital era. The need to engineer drugs to treat emerging diseases, an increase in the geriatric population...

NNVC : 3.36 (+1.82%)
GILD : 62.98 (-0.35%)
SRPT : 127.90 (-1.84%)
ABBV : 88.00 (-1.41%)
IONS : 60.13 (-2.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade GILD with:

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

2nd Resistance Point 63.95
1st Resistance Point 63.46
Last Price 62.98
1st Support Level 62.53
2nd Support Level 62.09

See More

52-Week High 70.50
Fibonacci 61.8% 66.83
Fibonacci 50% 65.69
Fibonacci 38.2% 64.56
Last Price 62.98
52-Week Low 60.89

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar